Professor Collins talks with journalist Aimee Donnellan about her book "Off the Scales" which describes the fascinating story behind the Ozempic GLP-1 Receptor Agonist (RA) medication. Their conversation covers the pivotal scientific developments of the drug, the stories of the overlooked women scientists who made key contributions to teh research, the broad societal impact of medications like Ozempic, and the personal stories of people taking it and how it affected their life and health. This episode delves into the science, ethics, usage and the future of medications for management of weight related health and wellbeing.
Key topics
- The science and development of Ozempic and GLP-1 RA medications
- The societal and health impact of diabetes and obesity management drugs
- The history of research and recognition of obesity as a disease
Resources
"Off the Scales - The Inside Story of Ozempic and the Race to Cure Obesity" by Amy Donnellan https://www.qbd.com.au/off-the-scales-the-inside-story-of-ozempic-and-the-race-to-cure-obesity/aimee-donnellan/9780008719098/
World Health Organization Guideline on GLP-1 RAs https://www.who.int/news/item/01-12-2025-who-issues-global-guideline-on-the-use-of-glp-1-medicines-in-treating-obesity
To access the Healthy Eating Quiz: Click on the top right hand 'green button' called 'How healthy is my diet' https://nomoneynotime.com.au/
Want a more Personalised Food, Nutrient Assessment Report? Use our Australian Eating Survey - For a 50% discount enter the 'DietCheck' code at the checkout! Purchase here https://australianeatingsurvey.com.au/
Here's the link to the No Money No Time closed Facebook group (be sure to take the Healthy Eating Quiz first) https://www.facebook.com/groups/386824626838448
Our No Money No Time email: nmnt@newcastle.edu.au and our Nutrition Science Bites email: nutritionsciencebites@newcastle.edu.au
Keywords: #Ozempic, #GLP1, #obesity, #weightmanagement, #AimeeDonnellan, #pharmaceuticalindustry, #health, #stigma, #sciencehistory, #drugdevelopment, #publichealth, #type2diabetes, #semaglutide